The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoNOVO
31 dez 2026
31 de dezembro de 2026
53%
$4,143 Vol.
31 de dezembro de 2026
$2,141 Vol.
53%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercado Aberto: Jun 22, 2026, 10:10 PM ET
Volume
$4,143Data de Término
1 jan 2027Mercado Aberto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$4,143Data de Término
1 jan 2027Mercado Aberto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions